DoD is extending information
collections requirements under current OMB Control Number
0720-0032. Pharmaceutical manufacturers will base refund
calculation on difference between average non-Federal price of drug
sold by pharmaceutical manufacturer to wholesalers, represented by
most recent annual non-Federal average manufacturing prices
(non-FAMP) and corresponding Federal Ceiling Price (FCP) or, at
discretion of pharmaceutical manufacturer, difference between FCP
and direct commercial contract sales price attributable to
applicable National Drug Code.
US Code:
10
USC 1074g(f) Name of Law: Pharmacy benefits program
There has been an increase in
the number of pharmaceutical manufacturers who have covered drugs
eligible for the TRRP. Based upon analysis of the utilization data
used in prior billings, DHA determined it needed to re-bill the 3rd
Quarter Calendar Year (QCY) 2009 to 4th QCY 2011 utilization data
during the last OMB renewal period. DHA does not anticipate that
re-billing additional quarters will be necessary. As a result, this
reduces the number of responses per respondent from 8 to 4
annually.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.